211At-MABG in Adults With Advanced Neuroendocrine Cancers

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT07661420
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Bronchial Carcinoid
  • Gastroenteropancreatic Neuroendocrine Neoplasm
  • Medullary Thyroid Cancer
  • Neuroendocrine Tumors
  • Paraganglioma
  • Pheochromocytoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 1 MBq/k of 211At-MABG Fractionated — DRUG
    Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)
  • 2 MBq/k1 of 211At-MABG Fractionated — DRUG
    Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)
  • 4 MBq/k of 211At-MABG Fractionated — DRUG
    Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)

Study Details

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).

Key Dates

Start date
Aug 1, 2026
Status verified
Jun 2026
Primary completion
Aug 1, 2029
Completion
Aug 1, 2032

Study Design

Enrollment
16 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Level -1: Fractionated 211At-MABG
    One treatment cycle (1 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (0.25 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).
  • Experimental: Dose Level 1: Fractionated 211At-MABG
    One treatment cycle (2 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (0.5 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).
  • Experimental: Dose Level 2: Fractionated 211At-MABG
    One treatment cycle (4 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (1 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).

Primary Outcome Measure

Evaluate overall study feasibility [ Time Frame: 4 weeks ]

Central Contacts

  • Abramson Cancer Center

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pennsylvania - Abramson Cancer CenterPhiladelphiaPennsylvania19104
Abramson Cancer Center
Vivek Narayan, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
University of Pennsylvania - Abramson Cancer Center· Philadelphia, PA

Related Studies